Troy Ignelzi Buys 19,000 Shares of Contineum Therapeutics

Troy Ignelzi, an insider at Contineum Therapeutics, Inc. (NasdaqGS: CTNM), purchased 19,000 shares on June 26, 2026. This transaction was not part of a pre-planned trading program and adds to the insider activity within the company.

Insider Buying and Selling at Contineum Therapeutics, Inc.

On June 26, 2026, several insiders, including Troy Ignelzi, Lori Lyons-Williams, Diego Miralles, Todd Brady, Olivia Ware, Sarah Boyce, and Evert Schimmelpennink, each bought 19,000 shares of Contineum Therapeutics. These purchases were not made under Rule 10b5-1 plans, indicating a direct interest in the company's stock.

Other Institutional Activity in Contineum Therapeutics

Among institutional investors, Janus Henderson Group PLC increased its holdings in Contineum Therapeutics by 285,857 shares, reaching a total of 2,734,836 shares valued at approximately $35.6 million, reflecting an 11.7% increase. Millennium Management LLC significantly boosted its position, adding 704,762 shares for a total of 1,535,449 shares worth about $20.1 million, marking an 84.8% increase. Conversely, Franklin Resources Inc. reduced its holdings by 40,140 shares, ending with 1,839,227 shares valued at $24 million, a 2.1% decrease. Balyasny Asset Management L.P. also cut its stake by 157,165 shares, resulting in 1,685,635 shares valued at $22 million, an 8.5% decrease.

Contineum Therapeutics, Inc. Stock Down 16.8%

Shares of Contineum Therapeutics traded near $13.36 on Saturday. The company has a market cap of approximately $530.5 million and a forward P/E ratio that is not meaningful due to negative earnings. With a beta of 0.89, the stock has experienced a 52-week range between $3.72 and $16.33. Its 50-day moving average stands at $13.02, while the 200-day moving average is $12.53. The company's strong liquidity is reflected in a current ratio of 38.0 and a quick ratio of 37.0, alongside a debt-to-equity ratio of 2.78.

Analysts Set New Price Targets

Morgan Stanley maintained its hold rating for Contineum Therapeutics with a price target of $16.00 on May 14, 2026. Baird has consistently rated the stock as a buy, with a target of $20.00 as of March 6, 2026. RBC Capital also maintained a buy rating with a target price of $22.00. The consensus among analysts is a strong buy, with an average target price of $22.33 based on six analyst opinions.

About Contineum Therapeutics

Contineum Therapeutics, Inc., based in San Diego, California, is a clinical-stage biopharmaceutical company. It focuses on developing small molecule therapies for conditions related to neuroscience, inflammation, and immunology. The company’s leading product candidates include PIPE-791 for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307 for depression and multiple sclerosis. Led by CEO Carmine N. Stengone, Contineum Therapeutics employs 51 people and continues to innovate in the biotechnology sector.

Bottom Line

Insider buying at Contineum Therapeutics, particularly by Troy Ignelzi and others, suggests a positive outlook from those closest to the company. Shares traded near $13.36, with the company holding a significant position in the biotech field. Investors often watch insider transactions for potential signals, though these do not necessarily predict future stock performance.